

Community Urine Isolates, All Ages

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from patient urine specimens submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2024 and 12/31/2024 for all isolates. These data are based on computer analysis of isolates not defined as healthcare associated: community isolates are defined as those collected in an outpatient setting. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Antimicrobials																									
		Amikacin	Amoxicillin + Clavulanate	Ampicillin	Ampicillin + Sulbactam	Cefazolin	Cefepime	Ceftaroline	Ceftazidime	Ceftriaxone	Cephalexin	Ciprofloxacin	Doxycycline	Ertapenem	Gentamicin	Levofloxacin	Linezolid	Meropenem	Minocycline	Nafcillin	Nitrofurantoin	Piperacillin + Tazobactam	Tetracycline	Tigecycline	Tobramycin	Trimethoprim + Sulfamethoxazole	Vancomycin
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
Citrobacter freundii	33	—	0	0	0	0	100	—	84	84	—	78	—	100	93	78	—	100	78	—	93	84	75	96	93	87	—
Citrobacter koseri	73	—	97	0	97	94	100	—	100	100	—	100	—	100	100	100	—	100	98	—	50	100	100	100	100	100	—
Citrobacter species	39	—	0	0	0	0	100	—	87	87	—	89	—	100	94	92	—	100	87	—	94	89	—	97	94	92	—
Coagulase Negative Staphylococcus species	136	—	—	—	—	—	98	—	—	—	—	84	—	94	—	100	—	—	56	100	—	—	—	—	—	60	100
Enterobacter cloacae complex	68	—	0	0	0	0	92	—	85	80	—	89	—	89	97	92	—	100	88	—	32	83	88	95	97	88	—
Enterococcus faecalis	398	—	—	99	—	—	—	—	—	—	—	32	—	—	—	99	—	—	—	98	—	—	—	—	—	—	99
E. coli	3574	—	89	57	62	77	92	—	93	90	88	71	—	99	91	79	—	99	90	—	97	97	76	99	91	79	—
Klebsiella aerogenes	84	—	0	0	0	0	100	—	85	85	—	98	—	96	100	100	—	98	92	—	52	84	95	97	100	100	—
Klebsiella oxytoca	75	—	95	0	27	16	97	—	97	96	—	100	—	100	100	100	—	100	94	—	94	94	96	97	98	97	—
Klebsiella pneumoniae	764	—	95	0	80	81	93	—	92	92	91	85	—	99	96	90	—	100	84	—	60	89	83	95	95	89	—
Proteus mirabilis	308	—	98	89	96	2	99	—	99	97	96	92	—	100	88	93	—	100	0	—	0	99	0	0	91	89	—
Pseudomonas aeruginosa	153	97	—	—	—	95	—	96	—	—	75	—	—	—	69	—	93	—	—	—	95	—	—	97	—	—	—
Serratia marcescens	48	—	0	0	0	0	95	—	97	87	—	91	—	100	100	97	—	100	79	—	0	89	—	66	52	100	—

Emergency Department - Urines

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from Inpatient urine specimens collected in the emergency department and submitted to the UNC Microbiology Laboratory between 1/1/2024 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Antimicrobials																										
		Amikacin	Amoxicillin + Clavulanate	Ampicillin	Ampicillin + Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftaroline	Ceftazidime	Ceftriaxone	Cephalexin	Ciprofloxacin	Doxycycline	Ertapenem	Gentamicin	Levofloxacin	Linezolid	Meropenem	Minocycline	Nafcillin	Nitrofurantoin	Piperacillin + Tazobactam	Tetracycline	Tigecycline	Tobramycin	Trimethoprim + Sulfamethoxazole	Vancomycin
Coagulase Negative Staphylococcus species	43	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
Enterobacter cloacae complex	57	—	0	0	0	64	0	87	—	63	61	—	80	—	76	94	82	—	98	92	—	45	63	85	94	94	84	—
Enterococcus faecalis	215	—	—	99	—	—	—	—	—	—	—	—	—	27	—	—	—	99	—	—	—	99	—	—	—	—	—	97
E. coli	1584	—	87	50	57	88	72	88	—	89	86	84	67	—	99	91	75	—	99	89	—	97	96	72	99	90	75	—
Klebsiella aerogenes	58	—	0	0	0	81	0	94	—	78	79	—	94	—	98	98	96	—	100	87	—	41	73	91	92	98	98	—
Klebsiella oxytoca	33	—	87	0	28	84	21	90	—	90	84	—	90	—	100	90	100	—	100	93	—	93	87	90	96	90	93	—
Klebsiella pneumoniae	366	—	90	0	70	84	76	85	—	84	84	84	78	—	98	90	86	—	99	82	—	64	83	78	93	90	81	—
Proteus mirabilis	144	—	97	86	93	99	5	98	—	99	97	95	81	—	100	87	82	—	100	0	—	0	99	0	—	88	86	—
Pseudomonas aeruginosa	132	100	—	—	—	—	—	96	—	94	—	—	81	—	—	100	64	—	96	—	—	—	92	—	—	100	—	—
Serratia marcescens	37	—	0	0	0	100	0	97	—	100	91	—	89	—	100	100	94	—	100	78	—	0	86	—	78	51	100	—

Aerobic Organisms, Inpatient Non-ICU, Urine Isolates, Adult Only

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from patient urine specimens (excluding ICU) submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2024 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Antimicrobials																								
		Amikacin	Amoxicillin + Clavulanate	Ampicillin	Ampicillin + Sulbactam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Cephalexin	Ciprofloxacin	Daptomycin	Doxycycline	Ertapenem	Gentamicin	Levofloxacin	Linezolid	Meropenem	Minocycline	Nitrofurantoin	Piperacillin + Tazobactam	Tetracycline	Tigecycline	Tobramycin	Trimethoprim + Sulfamethoxazole	Vancomycin
Enterobacter cloacae complex	61	—	0	0	0	0	81	52	50	—	78	—	—	74	93	78	—	98	85	42	54	81	91	93	77	—
E. coli	876	0	87	50	58	74	84	87	82	81	64	—	—	99	89	70	—	100	85	95	95	69	99	88	74	—
Enterococcus faecalis	183	—	—	98	—	—	—	—	—	—	100	27	—	—	—	98	—	—	99	—	—	—	—	—	—	97
Enterococcus faecium	56	—	—	5	—	—	—	—	—	—	100*	16	—	—	—	98	—	—	25	—	—	—	—	—	—	34
Klebsiella aerogenes	31	—	0	0	0	0	96	67	67	—	100	—	—	100	100	100	—	100	87	41	61	93	90	100	100	—
Klebsiella pneumoniae	309	—	85	0	63	66	76	76	75	75	71	—	—	97	87	80	—	98	78	56	78	71	90	85	74	—
Pseudomonas aeruginosa	162	98	—	—	—	—	93	88	—	—	78	—	—	—	100	64	—	90	—	—	85	—	—	96	—	—


* The percentage is Susceptible Dose-Dependent for E. faecium and Daptomycin

Pediatric Inpatient Urine Isolates Only

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from pediatric inpatient unit urine specimens submitted to the University of North Carolina Health Care Microbiology Laboratory between 1/1/2024 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Antimicrobial Susceptibility																			
		Amoxicillin + Clavulanate	Ampicillin	Ampicillin + Sulbactam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Cephalexin	Ciprofloxacin	Ertapenem	Gentamicin	Levofloxacin	Meropenem	Minocycline	Nitrofurantoin	Piperacillin + Tazobactam	Tetracycline	Tigecycline	Tobramycin	Trimethoprim + Sulfamethoxazole
E. coli	37	83	29	38	67	91	97	91	89	59	100	72	67	100	91	100	97	56	100	72	56



Emergency Department - Non-Urines

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from Inpatient specimens (excluding urines) collected in the emergency department and submitted to the UNC Microbiology Laboratory between 1/1/2024 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Antimicrobials																											
		Amoxicillin + Clavulanate	Ampicillin	Ampicillin + Sulbactam	Cefazolin	Cefepime	Ceftaroline	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Ertapenem	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Meropenem	Minocycline	Nafcillin	Piperacillin + Tazobactam	Rifampin	Tetracycline	Tigecycline	Tobramycin	Trimethoprim + Sulfamethoxazole	Vancomycin	
Coagulase Negative Staphylococcus species	114	—	—	—	—	—	99	—	—	—	60	—	68	—	28	85	—	100	—	—	42	—	98	—	—	—	—	58	100
Enterococcus faecalis	57	—	100	—	—	—	—	—	—	—	—	—	—	—	—	—	—	93	—	—	—	—	—	—	—	—	—	97	
E. coli	216	85	45	52	74	82	—	83	78	63	—	—	—	99	—	85	72	—	100	90	—	95	—	70	100	83	71	—	
Klebsiella pneumoniae	76	84	0	61	64	76	—	74	72	71	—	—	—	98	—	82	77	—	98	81	—	69	—	71	92	80	71	—	
Methicillin-Resistant Staphylococcus aureus	142	—	—	—	—	—	87	—	—	—	78	100	83	—	13	98	—	100	—	—	0	—	100	—	—	—	85	100	
Methicillin-Susceptible Staphylococcus aureus	180	—	—	—	—	—	98	—	—	—	71	100	93	—	58	99	—	100	—	—	100	—	99	—	—	—	97	100	
Pseudomonas aeruginosa	86	—	—	—	—	98	—	97	—	82	—	—	—	—	—	—	81	—	98	—	—	95	—	—	—	95	—	—	

Aerobic Organisms, Inpatient Non-ICU, Non-Urine Isolates, Adult Only

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from inpatient specimens (excluding urines) submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2024 and 12/31/2024. These data are based on computer analysis of isolates defined as healthcare associated; i.e. those collected in an inpatient setting; excluding samples from the ICU. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Antimicrobial Susceptibility (%)																											
		Amikacin	Amoxicillin + Clavulanate	Ampicillin	Ampicillin + Sulbactam	Cefazolin	Cefepime	Ceftaroline	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Ertapenem	Gentamicin	Levofloxacin	Linezolid	Meropenem	Minocycline	Nafcillin	Piperacillin + Tazobactam	Rifampin	Tetracycline	Tigecycline	Tobramycin	Trimethoprim + Sulfamethoxazole	Vancomycin
Acinetobacter baumannii complex	45	93	0	—	86	—	72	—	75	—	77	—	—	—	—	93	84	—	80	100	—	64	—	—	—	93	—	—	
Coagulase Negative Staphylococcus species	216	—	—	—	—	—	98	—	—	—	55	100	76	30	—	85	—	100	—	—	36	—	96	—	—	—	48	100	
Enterobacter cloacae complex	105	—	0	0	0	80	—	56	53	90	—	—	—	—	74	96	95	—	99	87	—	56	—	88	94	94	92	—	
Enterococcus faecalis	166	—	—	100	—	—	—	—	—	—	—	—	—	—	100	0	—	—	—	—	—	—	—	—	—	—	—	100	
Enterococcus faecium	93	—	—	13	—	—	—	—	—	—	—	—	—	—	98*	—	—	—	—	99	—	—	—	—	—	—	—	35	
E. coli	381	—	78	40	46	61	76	—	77	72	57	—	—	—	—	99	82	65	—	99	87	—	91	—	65	99	80	67	—
Klebsiella aerogenes	52	—	0	0	0	0	96	—	55	55	92	—	—	—	—	98	100	96	—	100	88	—	48	—	90	92	100	100	—
Klebsiella oxytoca	36	—	83	0	27	16	91	—	88	80	91	—	—	—	—	100	88	100	—	100	100	—	83	—	91	100	86	88	—
Klebsiella pneumoniae	219	—	84	0	56	60	74	—	72	72	68	—	—	—	—	98	85	80	—	98	77	—	71	—	68	88	83	75	—
Methicillin-Resistant Staphylococcus aureus	443	—	—	—	—	—	—	88	—	—	—	64	98	77	16	—	98	—	100	—	—	0	—	98	—	—	—	88	100
Methicillin-Susceptible Staphylococcus aureus	469	—	—	—	—	—	—	99	—	—	—	72	100	95	59	—	97	—	99	—	—	100	—	99	—	—	97	100	
Proteus mirabilis	65	—	98	90	92	3	98	—	96	96	80	—	—	—	—	98	93	81	—	100	0	—	98	—	0	100	96	95	—
Pseudomonas aeruginosa	383	—	—	—	—	—	87	—	85	—	79	—	—	—	—	—	33	68	—	86	—	81	—	—	—	—	97	—	—
Serratia marcescens	84	—	0	0	0	0	98	—	98	89	86	—	—	—	—	97	97	94	—	97	77	—	89	—	—	70	53	50	—
Stenotrophomonas maltophilia	123	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	91	—	—	100	—	—	—	—	—	—	99	—

* The percentage is Susceptible Dose-Dependent for E. faecium and Daptomycin

ICU All Isolates, All Ages

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from Adult ICU specimens (excluding the Burn ICU) submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2024 and 12/31/2024 for all isolates. These data are based on computer analysis of isolates not defined as healthcare associated; i.e. those collected in an inpatient ICU setting. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Antimicrobials																									
		Amoxicillin + Clavulanate	Ampicillin	Ampicillin + Sulbactam	Cefazolin	Cefepime	Ceftaroline	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Ertapenem	Gentamicin	Levofloxacin	Linezolid	Meropenem	Minocycline	Nafcillin	Piperacillin + Tazobactam	Tetracycline	Tigecycline	Tobramycin	Trimethoprim + Sulfamethoxazole	Vancomycin
Enterobacter cloacae complex	39	0	0	0	0	69	—	46	35	89	—	—	—	—	62	94	92	—	100	84	—	48	87	92	92	89	—
Enterococcus faecalis	46	—	100	—	—	—	—	—	—	—	—	100	27	—	—	—	—	100	—	—	—	—	—	—	—	—	100
Enterococcus faecium	46	—	4	—	—	—	—	—	—	—	—	93*	—	—	—	—	—	100	—	—	—	—	—	—	—	—	26
E. coli	102	76	38	45	53	74	—	74	70	61	—	—	—	98	86	63	—	98	84	—	82	62	97	83	64	—	
Klebsiella pneumoniae	76	86	0	57	61	73	—	72	72	69	—	—	—	98	89	82	—	98	76	—	76	68	87	88	75	—	
Methicillin-Resistant Staphylococcus aureus	120	—	—	—	—	—	78	—	—	—	52	98	72	24	—	98	—	100	—	—	0	—	—	—	—	95	100
Methicillin-Susceptible Staphylococcus aureus	88	—	—	—	—	—	96	—	—	—	78	100	100	68	—	98	—	98	—	100	—	—	—	—	97	100	
Pseudomonas aeruginosa	141	—	—	—	—	83	—	77	—	83	—	—	—	—	—	0	69	—	79	—	73	—	—	—	95	—	
Stenotrophomonas maltophilia	60	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	93	—	—	100	—	—	—	—	—	100	—

* The percentage is Susceptible Dose-Dependent for E. faecium and Daptomycin

Pediatric Inpatient, Non-Urine Isolates

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from pediatric inpatient unit specimens (excluding urines) submitted to the University of North Carolina Health Care Microbiology Laboratory between 1/1/2024 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Antimicrobials																										
		Amoxicillin + Clavulanate	Ampicillin	Ampicillin + Sulbactam	Cefazolin	Cefepime	Ceftaroline	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Ertapenem	Gentamicin	Levofloxacin	Linezolid	Meropenem	Minocycline	Nafcillin	Piperacillin + Tazobactam	Rifampin	Tetracycline	Tigecycline	Tobramycin	Trimethoprim + Sulfamethoxazole	Vancomycin
Coagulase Negative Staphylococcus species	34	—	—	—	—	—	93	—	—	—	21	100	82	18	—	35	—	100	—	—	20	—	97	—	—	—	41	100
E. coli	63	82	30	37	63	85	—	91	84	57	—	—	—	100	66	66	—	100	91	—	96	—	57	100	66	50	—	
Methicillin-Resistant Staphylococcus aureus	37	—	—	—	—	—	94	—	—	—	80	94	97	19	—	94	—	100	—	—	0	—	100	—	—	—	97	100
Methicillin-Susceptible Staphylococcus aureus	41	—	—	—	—	—	100	—	—	—	70	100	100	59	—	95	—	100	—	—	100	—	100	—	—	—	100	100
Pseudomonas aeruginosa	44	—	—	—	—	81	—	84	—	88	—	—	—	—	—	—	72	—	86	—	—	75	—	—	—	86	—	—

Aerobic Organisms, Cystic Fibrosis Cultures

Antimicrobial susceptibility of frequently encountered aerobic bacteria recovered from CF respiratory specimens submitted to the University of North Carolina Health Care Microbiology Laboratory between 1/1/2024 and 12/31/2024, all isolates. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Ceftaroline	Ceftazidime	Ciprofloxacin	Clindamycin	Doxycycline	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Meropenem	Minocycline	Nafcillin	Piperacillin + Tazobactam	Tobramycin	Trimethoprim + Sulfamethoxazole	Vancomycin
		S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
Methicillin-Resistant Staphylococcus aureus	81	88	—	—	39	88	8	97	—	100	—	—	0	—	—	92	100
Methicillin-Susceptible Staphylococcus aureus	256	99	—	—	60	98	53	96	—	100	—	—	100	—	—	98	100
Stenotrophomonas maltophilia	35	—	—	—	—	—	—	—	82	—	—	100	—	—	—	97	—
Mucoid Pseudomonas aeruginosa	169	—	84	43	—	—	—	—	33	—	88	—	—	86	82	—	—
Smooth Pseudomonas aeruginosa	163	—	82	53	—	—	—	—	44	—	79	—	—	84	73	—	—

Aerobic Streptococcus spp., All Isolates, All Ages

Antimicrobial susceptibility of Streptococcus species recovered from all specimens submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2024 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

	Total Isolates	Ceftriaxone	Ceftriaxone CSF	Clindamycin	Erythromycin	Penicillin G	Penicillin G CSF	Vancomycin
Organisms		S	S	S		S	S	S
Streptococcus agalactiae (group b)	59	—	—	47	33	100	—	100
Streptococcus mitis group	52	88	—	80	29	57	—	100
Streptococcus pneumoniae	89	96	79	71	28	95	59	100

Yeast, All Ages

Antimicrobial susceptibility of frequently encountered yeasts recovered from patient specimens submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2023 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

	Total Isolates	Fluconazole	Micafungin	Voriconazole
Organisms		S	S	S
Candida albicans	153	89	98	90
Candida dubliniensis	12	100	100	100
Candida glabrata	157	84*	96	0
Candida krusei	9	0	88	100
Candida parapsilosis complex	66	89	97	95
Candida tropicalis	38	55	100	52

* Percentage susceptible dose-dependent for *C. glabrata* and fluconazole

Mycobacteria, All Ages

Antimicrobial susceptibility of frequently encountered acid-fast bacilli recovered from patient specimens submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2023 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY

Organisms	Total Isolates	Susceptibility Legend															
		Amikacin	Amikacin (IV)	Amikacin (liposomal, inhaled)	Cefoxitin	Ciprofloxacin	Clarithromycin	Doxycycline	Ethambutol	Imipenem	Isoniazid	Linezolid	Moxifloxacin	Pyrazinamide	Rifampin	Tobramycin	Trimethoprim + Sulfamethoxazole
Mycobacterium abscessus complex	170	94	—	—	4	0	34	0	—	2	—	36	0	—	—	—	15
Mycobacterium avium complex	129	—	45	91	—	—	98	—	—	—	—	2	5	—	—	—	—
Mycobacterium chelonae	21	80	—	—	0	0	90	19	—	0	—	61	0	—	—	90	19
Mycobacterium fortuitum complex	30	100	—	—	16	100	20	20	—	50	—	96	100	—	—	0	93
Mycobacterium tuberculosis complex	12	—	—	—	—	—	—	—	100	—	100	—	—	*100 (6)	100	—	—

M. avium complex: clofazimine median = 0.12, range (<=0.015-0.5)

M. abscessus complex: tigecycline median = 0.25, range (0.06->2)
M. chelonae: tigecycline median = 0.25, range (0.12-0.5)
M. fortuitum: tigecycline median = 0.12, range (<0.03-0.25)

*Pyrazinamide testing is currently only available by pncA mutation analysis. Of those tested (n=6), no mutations were detected.

Nocardia, All Ages

Antimicrobial susceptibility of frequently encountered *Nocardia* recovered from patient specimens submitted to the University of North Carolina Hospitals Microbiology Laboratory between 1/1/2023 and 12/31/2024. Results are expressed as percent of strains tested to be susceptible by in vitro susceptibility testing. Strains yielding intermediate results together with resistant strains account for the balance. Susceptibility data are included only if more than 30 isolates were tested unless considered significant. In cases where fewer than 30 isolates were tested for a specific drug, the number of isolates may not be a large enough sampling size to have statistical validity.

UNCH MCLENDON LABORATORY


Organisms	Total Isolates													
		Amox/Clav	Ceftriaxone	Imipenem	Ciprofloxacin	Moxifloxacin	Clarithromycin	Amikacin	Tobramycin	Doxycycline	Minocycline	Trimethoprim + Sulfamethoxazole	Linezolid	
N. nova complex	17	12	59	0	0	0	100	100	0	0	0	100	100	

Table 8. Expected Antibicrobial Susceptibility Patterns of the Most Commonly Isolated *Nocardia* spp.

From CLSI M24S-Ed2:2023 Performance Standards for Susceptibility Testing of Mycobacteria, *Nocardia* spp., and Other Aerobic Actinomycetes, 2nd Edition

General Comments

- 1) Sulfonamides include trimethoprim-sulfamethoxazole.
- 2) Some *Nocardia* spp. may not exhibit expected patterns. Susceptibility testing is recommended for guiding treatment.

Species/Complex	Amikacin	Amoxicillin-Clavulanate	Ceftriaxone	Ciprofloxacin	Clarithromycin	Imipenem	Linezolid	Minocycline	Sulfonamides	Tobramycin	Comments
<i>N. abscessus</i>	S	S	S	R	R	V	S	V	S	V	
<i>N. brasiliensis</i>	S	S	V	R	R	R	S	V	S	S	Most isolates of <i>N. brasiliensis</i> appear to be susceptible or intermediate to minocycline.
<i>N. cyriacigeorgica</i>	S	R	S	R	R	V	S	V	S	S	
<i>N. farcinica</i>	S	S	R	V	R	V	S	V	S	R	
<i>N. nova</i> complex	S	R	V	R	S	S	S	V	S	R	Members of the <i>N. nova</i> complex include but are not limited to <i>N. africana</i> , <i>N. elegans</i> , <i>N. kruczakiae</i> , <i>N. nova</i> , and <i>N.</i>
<i>N. otitidiscaviarum</i>	S	R	R	V	V	R	S	V	S	S	
<i>N. pseudobrasiliensis</i>	S	R	R	S	S	R	S	R	V	S	
<i>N. transvalensis</i> complex	R	V	S	S	R	V	S	V	S	R	Members of the <i>N. transvalensis</i> complex include <i>N. blacklockiae</i> , <i>N. transvalensis</i> , and <i>N. wallacei</i>

Abbreviations: R, resistant; S, susceptible; V, variable

